$274 Million is the total value of SR ONE CAPITAL MANAGEMENT, LP's 5 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 25.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARCELLX INC. | $170,390,217 | +65.1% | 5,500,007 | 0.0% | 62.20% | +31.8% | ||
| DSGN | Buy | DESIGN THERAPEUTICS INC | $66,961,644 | -28.8% | 6,526,476 | +16.0% | 24.44% | -43.2% |
| SBTX | New | ARS PHARMACEUTICALS | $25,672,544 | – | 3,009,677 | +100.0% | 9.37% | – |
| NKTX | NKARTA INC. | $7,986,665 | -54.5% | 1,333,333 | 0.0% | 2.92% | -63.7% | |
| EFFECTOR THERAPEUTICS INC | $2,933,509 | -24.6% | 6,822,114 | 0.0% | 1.07% | -39.8% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-08
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DESIGN THERAPEUTICS INC | 8 | Q3 2023 | 68.1% |
| EFFECTOR THERAPEUTICS INC | 8 | Q3 2023 | 31.9% |
| ARCELLX INC. | 7 | Q3 2023 | 72.6% |
| NKARTA INC. | 6 | Q3 2023 | 8.0% |
| ARS PHARMACEUTICALS INC | 4 | Q3 2023 | 11.6% |
| MINERALYS THERAPEUTICS INC | 3 | Q3 2023 | 13.2% |
View SR ONE CAPITAL MANAGEMENT, LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-12 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-10 |
| 13F-HR/A | 2023-05-19 |
| 13F-HR | 2023-05-09 |
| 13F-HR | 2023-02-08 |
| 13F-HR | 2022-11-08 |
| 13F-HR | 2022-08-02 |
| 13F-HR | 2022-05-10 |
| 13F-HR | 2022-02-14 |
View SR ONE CAPITAL MANAGEMENT, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.